Clinical trials: Advanced Solid Tumors Patients
Advanced Solid Tumor
A Study of BPI-460372 in Advanced Solid Tumor Patients
This study is an open-label, single arm, dose escalation and dose expansion phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BPI-460372 in solid tumor patients.
- Trial name
- NCT05789602
- Testing
- BPI-460372
- Where
- 11 sites in China
- Volunteers
- 82 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
RATIONALE: Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006257
- Testing
- paclitaxel, semaxanib
- Where
- 3 sites in United States
- Sponsor
- City of Hope Medical Center
Advanced Malignant Solid Tumors
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard…
- Trial name
- NCT06231550
- Testing
- FC084CSA tablets
- Where
- China
- Volunteers
- 21 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Advanced Malignant Solid Tumor
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors
This research study is evaluating a new type of personalized neoantigen cancer vaccine（iNeo-Vac-P01）combined with anti-PD-1 antibody and radiofrequency ablation as a possible treatment for patients with advanced solid tumors.
- Trial name
- NCT04864379
- Testing
- iNeo-Vac-P01, GM-CSF, PD-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Advanced Solid Tumor
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
Despite recent advances in the treatment of solid tumors in general, advanced (metastatic) disease remains mostly incurable and there is an urgent need to develop new therapeutic options for these patients, particularly…
- Trial name
- NCT05076396
- Testing
- PM14
- Where
- 9 sites in United States, France and 1 more
- Volunteers
- 126 people
- Sponsor
- PharmaMar
Epithelial Cancer Patients
Phase I/IIa Clinical Trial of IMC001 in Patients With Advanced Epithelial Solid Tumors.
This is an open -label phase I /IIa study designed to evaluate the safety and efficacy of IMC001 in patients with advanced epithelial solid tumors.
- Trial name
- IMC001 EpCAM (NCT07644403)
- Testing
- Autologous CAR-T cell injection targeting EpCAM
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Solid Tumors
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
This is an open-label, multicenter, dose-escalation and expansion Phase Ib clinical study of RO6958688 in combination with atezolizumab. Part I of the study is subdivided into parts IA and IB.
- Trial name
- NCT02650713
- Testing
- Atezolizumab, RO6958688
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 228 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Solid Tumor, Metastatic Cancer
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
This is a Phase 1, open-label, first-in-human study of CTX-471 administered as a monotherapy or in combination with pembrolizumab in patients with metastatic or locally advanced malignancies that have progressed while receiving…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Cancer, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT03881488
- Testing
- CTX-471, Pembrolizumab (KEYTRUDA®)
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Compass Therapeutics
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
This phase I trial studies the side effects and best dose of entinostat and nivolumab when given together with ipilimumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma
- Trial name
- NCT02453620
- Testing
- Biopsy Procedure, Blood Sample, Bone Scan
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
In this study, BKM120 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists.
- Trial name
- NCT01283503
- Testing
- BKM120
- Where
- 2 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory
TR115 in Patients With Relapsed / Refractory Non-Hodgkin's Lymphoma or Advanced Solid Tumors
A phase 1 dose escalation and expanded cohort study of TR115 in the treatment of adult patients with relapsed/refractory non-hodgkin's lymphoma or advanced solid tumors.
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor
- Trial name
- NCT05650580
- Testing
- TR115
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tarapeutics Science Inc.
Advanced Solid Tumors
An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma
Use PT-112 alone for Phase I dose escalation stage: advanced solid tumors, Phase I dose confirmation stage: advanced solid tumors. Phase II hepatocellular carcinoma (HCC).
- Trial name
- NCT03439761
- Testing
- PT-112 Injection
- Where
- China
- Volunteers
- 125 people
- Sponsor
- SciClone Pharmaceuticals
Solid Tumors, Lymphomas
Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas
A Phase 1/2a, dose-escalation study of FF-10502-01 in Patients with Advanced Solid Tumors and Lymphomas. A total of up to 9 cohorts will be enrolled in Phase 1 to establish the Maximum Tolerated Dose (MTD).
- Trial name
- NCT02661542
- Testing
- FF-10502-01
- Where
- 2 sites in United States
- Volunteers
- 106 people
- Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
Solid Tumor, Ovarian Cancer
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
- Trial name
- NCT06531486
- Testing
- XS-02 capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer, Advanced Solid Tumor
A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors
This is a Phase 1 dose escalation and dose expansion phase I study to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of RGT-419B as monotherapy in Chinese patients with HR+/HER2…
- Trial name
- NCT06299124
- Testing
- RGT-419B
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Regor Pharmaceuticals Inc.
Malignant Neoplasms
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Phase I study of IMMH-010 in patients with advanced malignant solid tumors
- Trial name
- NCT04343859
- Testing
- IMMH-010
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Tianjin Chasesun Pharmaceutical Co., LTD
Advanced Solid Tumors, Metastatic Solid Tumors
NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies
This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic…
- Trial name
- IMMUNONET (NCT05605496)
- Testing
- NP137, anti-PD-1/PD-L1
- Where
- 5 sites in France
- Volunteers
- 57 people
- Sponsor
- Centre Leon Berard
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This phase II Pediatric MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma
- Trial name
- NCT03155620
- Testing
- Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy
- Where
- 172 sites in United States, Australia and 2 more
- Volunteers
- 1,377 people
- Sponsor
- National Cancer Institute (NCI)
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
Study of CPI-200 in Patients With Advanced Tumors
This is a prospective, open-label, single arm, non-randomized study of CPI-200 in patients with advanced tumors. CPI-200 is administered via intravenous infusion using an accelerated titration method followed by a conventional 3…
- Trial name
- NCT03953742
- Testing
- CPI-200
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Coordination Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.